DMD and Duchenne muscular dystrophy: The mutation-agnostic therapeutic approaches under development, such as gene therapies using adeno-associated viral vectors (AAVs) as a vehicle to deliver a miniaturized but functional dystrophin molecule (mini/micro-dystrophin), could be applicable to all DMD patients including those carrying duplications.